Testing new drug solnatide IMP in COVID-19 patients
Coronavirus disease 2019 (COVID-19) has turned into a pandemic with millions of infected individuals worldwide. Patients suffer from severe respiratory failure and a life-threatening pulmonary oedema (PPO) that leads to acute respiratory distress syndrome (ARDS) in 30 % of the cases. The EU-funded SOLNATIDE project aims to test the novel drug solnatide IMP in COVID-19 patients. Solnatide has already been tested in one Phase I and in two Phase II clinical studies for the treatment of ARDS. Given the lack of available drugs for treating patients infected with the new coronavirus, solnatide constitutes a promising solution for tackling the exacerbated pulmonary manifestations of the virus.
Call for proposal
See other projects for this call
Funding SchemeRIA - Research and Innovation action
20832 Palazzo Aliprandi
08777 Santa Quinti De Mediona